Ignite Creation Date:
2024-05-06 @ 8:10 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06286046
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-13
First Post:
2024-02-23
Brief Title:
A Study of Mitapivat in Participants With Sickle Cell Disease and Nephropathy
Sponsor:
Agios Pharmaceuticals Inc
Organization:
Agios Pharmaceuticals Inc
Study Overview
Official Title:
A Phase 2 Open-label Multicenter Study of Mitapivat in Subjects With Sickle Cell Disease and Nephropathy RESIST
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to evaluate the effect of mitapivat on albumin creatinine ratio ACR response in participants with sickle cell disease SCD and nephropathy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2023-510289-28-00 | OTHER | EU Clinical Trial Number | None |